title: Low molecular weight fucoidan ameliorating the chronic cisplatin-induced delayed gastrointestinal motility in rats.
abstract: Delayed gastrointestinal (GI) motility is frequent adverse effect associated with chemotherapy due to oxidative stress, activation of 5-HT3 receptors or serotonin releases from enterochromaffin cells. Fucoidan, extracts from brown seaweeds, has been showed antioxidant related favorable pharmacological activities including digestive tract protective effects. Low molecular weight fucoidan (LMF) obtained by acid hydrolysis of high molecular weight fucoidan has been showed more favorable bioactivities. This study was conducted to determine whether or not LMF can prevent delayed GI motility induced by the antineoplastic drug cisplatin chronically administered, once per week for five consecutive weeks. LMF ameliorating the chronic cisplatin treatment related body weight decreases, delayed GI motility, and enhanced the antioxidant defense systems. In addition, LMF also inhibited the cisplatin treatment related GI gastrin and serotonin changes, including enzyme activities involved in serotonin metabolism and enterochromaffin cells. The overall effects of LMF 10mg/kg were similar to that of ondansetron 1mg/kg, a serotonin 5-HT3 receptor antagonist. The present results supported that LMF have favorable ameliorating effect on the delayed GI motility induced by chemotherapy, modulated the GI enterochromaffin cells, serotonin and gastrin-producing cells with antioxidant effects. This effect of LMF may help improve accompanying digestive disorders by chemotherapy.
authors.affiliation: Korea Conformity Laboratories, Seoul 153-803, Republic of Korea.
authors.forename: Moon Yong
authors.initials: MY
authors.lastname: Song
authors.forename: Sae Kwang
authors.initials: SK
authors.lastname: Ku
authors.forename: Hyun Jee
authors.initials: HJ
authors.lastname: Kim
authors.forename: Jin Soo
authors.initials: JS
authors.lastname: Han
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects; D000975:Antioxidants / Q000494:pharmacology*; D002908:Chronic Disease; D002945:Cisplatin / Q000633:toxicity*; D004759:Enterochromaffin Cells / Q000187:drug effects / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects*; D008297:Male; D008970:Molecular Weight; D008995:Monoamine Oxidase / Q000378:metabolism; D017294:Ondansetron / Q000494:pharmacology; D011134:Polysaccharides / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044406:Receptors, Serotonin, 5-HT3 / Q000235:genetics / Q000378:metabolism; D012624:Seaweed / Q000737:chemistry; D012701:Serotonin / Q000378:metabolism; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000494:pharmacology; D014365:Tryptophan Hydroxylase / Q000378:metabolism; D044648:Undaria / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D011134:Polysaccharides; D044406:Receptors, Serotonin, 5-HT3; D058831:Serotonin 5-HT3 Receptor Antagonists; D012701:Serotonin; D017294:Ondansetron; C007789:fucoidan; D014365:Tryptophan Hydroxylase; D008995:Monoamine Oxidase; D002945:Cisplatin